Annotation Detail

Information

Associated Genes: ALK
Associated Variants: ALK EML4-ALK C1156Y
Associated Disease: lung non-small cell carcinoma
Source Database: CIViC Evidence
Description: In this case report, a patient with metastatic, ALK-rearranged NSCLC with C1156Y mutation had tumor progression under sequential treatment with first crizotinib, then ceritinib and finally AUY922. Subsequent chemotherapy (carboplatin–pemetrexed) was administered and the patient had a response for 6 months before progression. Exome sequencing revealed the C1156Y mutation was present in <7% of the pretreatment tumor and in ~50% of the crizotinib tumor prior to ceritinib therapy.
Variant Origin: somatic
Variant Origin: Somatic
Evidence URL: https://civic.genome.wustl.edu/links/evidence_items/841
Gene URL: https://civic.genome.wustl.edu/links/genes/1
Variant URL: https://civic.genome.wustl.edu/links/variants/6
Rating: 3
Evidence Type: Predictive
Disease: Lung Non-small Cell Carcinoma
Evidence Direction: Supports
Drug: Ceritinib,Luminespib,Crizotinib
Evidence Level: C
Clinical Significance: Resistance
Pubmed: 26698910

Drugs